Perez-Garcia JM, Gebhart G, Ruiz Borrego M, Stradella A, et al. Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol 2021 May 18. pii: S1470-2045(21)00122.
PMID: 34019819